A. Dumitrașcu

PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers

G. Pruneri, A. Anichini, G. Galli, 2022, ESMO open.